title: Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women.
abstract: This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase. Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.
authors.affiliation: Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA. rsegraves@metrohealth.org
authors.forename: R T
authors.initials: RT
authors.lastname: Segraves
authors.forename: H
authors.initials: H
authors.lastname: Croft
authors.forename: R
authors.initials: R
authors.lastname: Kavoussi
authors.forename: J A
authors.initials: JA
authors.lastname: Ascher
authors.forename: S R
authors.initials: SR
authors.lastname: Batey
authors.forename: V J
authors.initials: VJ
authors.lastname: Foster
authors.forename: C
authors.initials: C
authors.lastname: Bolden-Watson
authors.forename: A
authors.initials: A
authors.lastname: Metz
mesh_terms: D000328:Adult; D000368:Aged; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010549:Personal Satisfaction; D012720:Severity of Illness Index; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis / Q000188:drug therapy*; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D018492:Dopamine Antagonists; D016642:Bupropion